HRP20010133B1 - Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases - Google Patents

Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Info

Publication number
HRP20010133B1
HRP20010133B1 HR20010133A HRP20010133A HRP20010133B1 HR P20010133 B1 HRP20010133 B1 HR P20010133B1 HR 20010133 A HR20010133 A HR 20010133A HR P20010133 A HRP20010133 A HR P20010133A HR P20010133 B1 HRP20010133 B1 HR P20010133B1
Authority
HR
Croatia
Prior art keywords
treatment
optically active
vascular diseases
oxadiazine derivative
pyridyl
Prior art date
Application number
HR20010133A
Other languages
English (en)
Inventor
Jednakovits Andrea
Urogdi Laszlo
Denes Laszlo
Kurucz Istvan
Marvanyos Ede
Barabas Mihaly
Bacsy Erno
Korom Zsuzsanna
Nagy Zoltan
Urge Laszlo
Szilbereky Jenoe
Acsai Karoly
Krajcsi Peter
Csakai Zita
Toeroek Magdolna
Original Assignee
Biorex Kutat� �S Fejleszt� Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �S Fejleszt� Rt. filed Critical Biorex Kutat� �S Fejleszt� Rt.
Publication of HRP20010133A2 publication Critical patent/HRP20010133A2/hr
Publication of HRP20010133B1 publication Critical patent/HRP20010133B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010133A 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases HRP20010133B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
HRP20010133A2 HRP20010133A2 (en) 2002-02-28
HRP20010133B1 true HRP20010133B1 (en) 2005-02-28

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010133A HRP20010133B1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Country Status (27)

Country Link
US (1) US6384029B1 (cg-RX-API-DMAC7.html)
EP (1) EP1147105B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532498A (cg-RX-API-DMAC7.html)
KR (1) KR100661774B1 (cg-RX-API-DMAC7.html)
AT (1) ATE266027T1 (cg-RX-API-DMAC7.html)
AU (1) AU765336B2 (cg-RX-API-DMAC7.html)
BG (1) BG65179B1 (cg-RX-API-DMAC7.html)
BR (1) BR9913982A (cg-RX-API-DMAC7.html)
CA (1) CA2340734C (cg-RX-API-DMAC7.html)
CZ (1) CZ300764B6 (cg-RX-API-DMAC7.html)
DE (1) DE69917074T2 (cg-RX-API-DMAC7.html)
DK (1) DK1147105T3 (cg-RX-API-DMAC7.html)
EE (1) EE04551B1 (cg-RX-API-DMAC7.html)
ES (1) ES2219091T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20010133B1 (cg-RX-API-DMAC7.html)
HU (1) HU226617B1 (cg-RX-API-DMAC7.html)
IL (1) IL141515A (cg-RX-API-DMAC7.html)
NO (1) NO317649B1 (cg-RX-API-DMAC7.html)
PL (1) PL196584B1 (cg-RX-API-DMAC7.html)
PT (1) PT1147105E (cg-RX-API-DMAC7.html)
RS (1) RS50129B (cg-RX-API-DMAC7.html)
RU (1) RU2222538C2 (cg-RX-API-DMAC7.html)
SI (1) SI1147105T1 (cg-RX-API-DMAC7.html)
SK (1) SK285582B6 (cg-RX-API-DMAC7.html)
UA (1) UA70340C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000035914A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200101182B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスOrphazyme Aps 酵素活性の調節因子としてのHsp70の使用
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
DE69628320D1 (de) * 1995-11-03 2003-06-26 Summit Packaging Systems Ltd Vorrichtung zum abgeben und füllen von beuteln an einem kassenplatz eines supermarkts
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
IL141515A0 (en) 2002-03-10
RS50129B (sr) 2009-03-25
EE200100188A (et) 2002-08-15
DE69917074T2 (de) 2005-05-12
DE69917074D1 (de) 2004-06-09
SK2342001A3 (en) 2001-08-06
WO2000035914A1 (en) 2000-06-22
PL196584B1 (pl) 2008-01-31
US6384029B1 (en) 2002-05-07
BG105342A (en) 2001-12-29
EE04551B1 (et) 2005-10-17
ES2219091T3 (es) 2004-11-16
CZ300764B6 (cs) 2009-08-05
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
CA2340734C (en) 2008-10-21
BR9913982A (pt) 2001-06-12
AU765336B2 (en) 2003-09-18
JP2011201916A (ja) 2011-10-13
YU25001A (sh) 2004-07-15
HU226617B1 (en) 2009-04-28
PT1147105E (pt) 2004-07-30
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
JP5620340B2 (ja) 2014-11-05
JP2002532498A (ja) 2002-10-02
HRP20010133A2 (en) 2002-02-28
BG65179B1 (bg) 2007-05-31
DK1147105T3 (da) 2004-06-01
CZ20011550A3 (cs) 2001-08-15
SK285582B6 (sk) 2007-04-05
CA2340734A1 (en) 2000-06-22
PL346767A1 (en) 2002-02-25
IL141515A (en) 2005-09-25
AU1790600A (en) 2000-07-03
ATE266027T1 (de) 2004-05-15
KR20010073129A (ko) 2001-07-31
UA70340C2 (en) 2004-10-15
NO20012310L (no) 2001-05-10
NO317649B1 (no) 2004-11-29
EP1147105A1 (en) 2001-10-24
NO20012310D0 (no) 2001-05-10
HUP9802897A2 (hu) 2000-11-28
EP1147105B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
GB0005251D0 (en) Therapeutic compounds
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GR3015879T3 (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use.
PL346767A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
BG106155A (en) Novel derivatives and analogues of galanthamin
IL109534A0 (en) Pour-on formulations containing polymeric material, glycols and glycerides and a process for their preparation
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
IL116384A0 (en) Ylidene compounds and their preparation
TR199901385T2 (xx) Piperidin t�revleri.
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
DE69511247D1 (de) Therapeutische benzonitrile
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20101124

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20111208